Prothena Corp Public (PRTA) Income from Continuing Operations (2012 - 2026)
Prothena Corp Public (PRTA) recorded quarterly Income from Continuing Operations of 32721000.0 in Q1 2026, up 251.56% quarter-over-quarter from 21589000.0 in Q4 2025, and up 154.36% on a YoY basis from 12864135.14 in Q1 2025.
Prothena Corp Public (PRTA) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Prothena Corp Public's Income from Continuing Operations history runs 15 years deep, the most recent figure standing at 32721000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 154.36% year-over-year to 32721000.0; the TTM figure through Mar 2026 stood at 151147000.0 (down 37.0% YoY), while the FY2025 annual figure was 244092000.0, down 99.57% from the prior year.
- Income from Continuing Operations was 32721000.0 for Q1 2026 at Prothena Corp Public, up from 21589000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 66847000.0 in Q2 2024 to a low of 125767000.0 in Q2 2025.
- Historically, Income from Continuing Operations has averaged 35157352.94 across 5 years, with a median of 45717000.0 in 2022.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations slumped 1162.62% in 2023, then surged 222.43% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 6349000.0 in 2022, then plunged by 1162.62% to 67466000.0 in 2023, then advanced by 14.06% to 57981000.0 in 2024, then surged by 62.77% to 21589000.0 in 2025, then soared by 251.56% to 32721000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 32721000.0 (Q1 2026), 21589000.0 (Q4 2025), and 36512000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Prothena Corp Public | 479.08 Mn | 149.61 Mn | - | 32.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.72 Mn |
| Dec 31, 2025 | -21.59 Mn |
| Sep 30, 2025 | -36.51 Mn |
| Jun 30, 2025 | -125.77 Mn |
| Mar 31, 2025 | -60.20 Mn |
| Dec 31, 2024 | -57.98 Mn |
| Sep 30, 2024 | -59.00 Mn |
| Jun 30, 2024 | 66.85 Mn |
| Mar 31, 2024 | -72.24 Mn |
| Dec 31, 2023 | -67.47 Mn |
| Sep 30, 2023 | 21.92 Mn |
| Jun 30, 2023 | -54.60 Mn |
| Mar 31, 2023 | -46.88 Mn |
| Dec 31, 2022 | 6.35 Mn |
| Sep 30, 2022 | -45.72 Mn |
| Jun 30, 2022 | -41.27 Mn |
| Mar 31, 2022 | -36.29 Mn |
| Dec 31, 2021 | -33.18 Mn |
| Sep 30, 2021 | 109.25 Mn |
| Jun 30, 2021 | 27.60 Mn |